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Acidification of synaptic vesicles by the vacuolar
proton ATPase is essential for loading with neuro-
transmitter. Debated findings have suggested that
V-ATPase membrane domain (V0) also contributes
to Ca2+-dependent transmitter release via a direct
role in vesicle membrane fusion, but the underlying
mechanisms remain obscure. We now report a direct
interaction between V0 c-subunit and the v-SNARE
synaptobrevin, constituting amolecular link between
the V-ATPase and SNARE-mediated fusion. Interac-
tion domains were mapped to the membrane-prox-
imal domain of VAMP2 and the cytosolic 3.4 loop of
c-subunit. Acute perturbation of this interaction with
c-subunit 3.4 loop peptides did not affect synaptic
vesicle proton pump activity, but induced a substan-
tial decrease in neurotransmitter release probability,
inhibiting glutamatergic as well as cholinergic trans-
mission in cortical slices and cultured sympathetic
neurons, respectively. Thus, V-ATPase may ensure
two independent functions: proton transportbya fully
assembled V-ATPase and a role in SNARE-depen-
dent exocytosis by the V0 sector.
INTRODUCTION
In nerve terminals, synaptic vesicles are loaded with neurotrans-
mitters and dock at active zones. Through a process called
priming they then acquire the ability to fuse and release their
contents in response to Ca2+ influx. It is largely admitted that
Ca2+ entry through voltage-gated channels is detected by the
Ca2+ sensor synaptotagmin that triggers the membrane fusion
machinery (Sudhof, 2004). A fusion pore connecting the vesicle268 Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc.lumen to the synaptic cleft opens and then expands, allowing
neurotransmitters to diffuse into the synaptic cleft. In an alterna-
tive mode, the pore may close without expanding, resulting in
transient or ‘‘kiss and run’’ release, which avoids vesicle collapse
into the plasma membrane (He et al., 2006; Smith et al., 2008;
Zhang et al., 2009).
The implication of SNARE proteins in vesicular transport is
ubiquitous in eukaryotes. Nerve terminals express the v-SNARE
synaptobrevin (VAMP2), anchored in the synaptic vesicle
membrane, and the t-SNAREs syntaxin 1 and SNAP-25, which
are predominantly inserted in the plasma membrane. The
assembly of synaptic SNARE complexes in a ‘‘trans’’ configura-
tion between a docked synaptic vesicle membrane and the
plasma membrane is a key process in membrane fusion. Dele-
tions or mutations in synaptic SNARE proteins and their specific
cleavage by clostridial neurotoxins have deleterious effects on
synaptic neurotransmitter release (Jahn and Scheller, 2006; Sud-
hof, 2004). It is generally accepted that SNAREs, assisted by the
synaptotagmin, can directly drive lipid bilayer fusion, but the
nature of the fusion pore is still a matter of debate and it seems
likely that distinctmodes of transmitter release reflect differences
in themolecular organization of themembrane fusionmachinery.
Themembrane-proximal part of theSNAREcomplex is thought to
play an important role in membrane fusion. The C-terminal end of
the SNARE complex can assemble and disassemble indepen-
dently (Sorensen et al., 2006). Introducing a linker at the VAMP2
juxtamembrane domain severely impairs evoked release (Deak
et al., 2006; Bretou et al., 2008), and the VAMP2 C-terminal
unstructured segment W89–N93 has been proposed to act as a
SNARE complex folding arrest signal (Ellena et al., 2009). In
VAMP2, mutating the juxtamembrane tryptophans that are
involved in interactions with calmodulin and lipids (Quetglas
et al., 2000) increasedspontaneous fusionanddecreasedevoked
release in neurons (Maximov et al., 2009), as well as reducing
Ca2+-dependent exocytosis in PC12 cells (Quetglas et al., 2002).
Thus, full SNARE assembly might provide force to mix lipids
mechanically or alternatively pin membranes together and
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Figure 1. Determinants of c-Subunit Inter-
action with VAMP2
(A) Alignments of c-subunit recombinant construc-
tions used in Y2H and their interaction with full-
length VAMP2.
(B) Summary of binary interactions between
c-subunit and SNARE constructs.
All experiments were reproduced at least four
times.
See also Figure S1.
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V-ATPase and SNAREs in Neurotransmitter Releaseprovide scaffolding for proteins that act downstream to form a
channel-like pore or catalyze rearrangements of lipid pore inter-
mediates (reviewed in Chernomordik and Kozlov, 2008; Jackson
and Chapman, 2008; Morel et al., 2001).
Several recent reports in different model systems implicate
the multimolecular V0 domain of the vacuolar proton ATPase
(V-ATPase) in membrane fusion (Hiesinger et al., 2005; Liegeois
et al., 2006; Peters et al., 2001; Sun-Wada et al., 2006).
V-ATPase is a large enzymatic complex expressed in all
eukaryotic cells, with the primary function of proton pumping.
It is omnipresent in intracellular membrane compartments,
including synaptic vesicles (Stevens and Forgac, 1997), where
it generates vesicular proton gradients and membrane potential
that underlie GABA/monoamine and glutamate uptake (Mor-
iyama et al., 1992). V-ATPase is composed of two reversibly
associated sectors, a peripheral multisubunit V1 sector that
hydrolyses ATP and a membrane V0 sector that translocates
protons. In mammals, V0 is composed of a rotor of six subunits
(5 c-subunits and 1 c00-subunit) and single copies of a-, d-, and
e-subunits.
Almost two decades ago, studies on Torpedo c-subunit (also
called V0 proteolipid or mediatophore) suggested that it forms
a pore mediating acetylcholine release (reviewed in Morel
et al., 2001). Peters et al. (2001) later demonstrated a crucial
role of V0 in yeast vacuolar fusion, downstream of SNARE
complex assembly, possibly via pore formation. A recent unbi-
ased genetic screen for synaptic malfunction in Drosophila has
identified the ortholog of the a1-subunit of V0 as an essential
component in synaptic vesicle fusion, also acting downstream
of SNAREs (Hiesinger et al., 2005). Moreover, independently
from its proton transport function, a role of the V-ATPase V0
sector has recently been demonstrated in the apical secretionNeuron 67, 268–of Hedgehog-related proteins mediated
by exosomes in C. elegans (Liegeois
et al., 2006), as well as insulin secretion
in pancreatic b cells (Sun-Wada et al.,
2006) and lysosome-phagosome fusion
in zebrafish (Peri and Nusslein-Volhard,
2008). The precise molecular action of
V0 in secretion/neurotransmitter release
is not yet clear and thus its direct involve-
ment remains a controversial issue.
Although earlier biochemical approaches
suggested that V-ATPase subunits and
SNAREs (Bennett et al., 1992; Galli
et al., 1996; O’Connor et al., 1993; Shiffet al., 1996) are associated in large protein complexes, evidence
for direct and regulated interaction is still missing.
We have therefore explored molecular links between SNAREs
and V-ATPase. Our results indicate direct binding of VAMP2 and
V0 c-subunit, an interaction that is regulated by Ca2+/calmod-
ulin. Mapping of the interaction domains and injection of a
mimetic peptide showed that acute perturbation of the VAMP2
c-subunit complex inhibits both central glutamatergic and
peripheral cholinergic neurotransmission.
RESULTS
VAMP2 Interacts with V0 c-Subunit
Yeast two-hybrid (Y2H) methods have not been widely used to
probe interactions between proteins with transmembrane (TM)
domains. However, detection of V0 c-subunit as a partner for
b1 integrin (Skinner and Wildeman, 1999) and identification of
a full-length (FL) syntaxin 1 clone in a screen via bSNAP as bait
(O.E.F., unpublished results) encouraged us to pursue Y2H
analysis of in vivo interactions between SNAREs and V0
subunits. Therefore, we used the LexA Y2H system to probe
for binding between c-subunit and VAMP2.
Our results showed that c-subunit binds to VAMP2 via an
interaction involving the C-terminal third of c-subunit, indicating
that the cytoplasmically oriented loop 3.4 is very likely to
constitute the VAMP2-binding domain (Figure 1A; Figure S1
available online). Control experiments confirmed robust binding
of FL VAMP2 to syntaxin1 and homodimerization of FL VAMP2
(Figure 1B). Interestingly, FL VAMP2 displayed an interaction
with c-subunit (Figure 1) whereas a VAMP2 construct lacking
the TM (VAMP2-DTM) did not. Two explanations can be envis-
aged: (1) VAMP2 TM carries the c-subunit binding site or (2)279, July 29, 2010 ª2010 Elsevier Inc. 269
Figure 2. The Membrane-Proximal Domain of VAMP2
Mediates Its Interaction with V0 c-Subunit
Wild-type mutant and truncation constructs of GST-VAMP2
fusion proteins were immobilized on glutathione beads and
used to pull down wild-type HSV-tagged c-subunit (c-2-155).
After SDS-PAGE, samples were immunoblotted and bound
c-2-155 was detected with anti-HSV antibodies. Arrowhead
indicates position of c-2-155 monomer.
(A) Pull-down of purified c-subunit (c-2-155) with either GST or
GST-VAMP2. Left: Coomassie blue staining of 3 mg c-2-155.
Right: specific binding of c-2-155 to GST-VAMP2-2-92
(GVD). Load lane contains 200 ng of purified c-2-155.
Note the presence of c-2-155 oligomers that resisted SDS
denaturation.
(B) Mapping of c-2-155 binding site on VAMP2. Binding of
c-2-155 to GST-VAMP2-28-92 (GV-28-92) but not to
GV-2-31 or GV-28-76. Load lane contains 50 ng of purified
c-2-155.
(C) Tryptophan residues 89 and 90 on VAMP2 are crucial
in mediating c-subunit interaction. c-2-155 binding to
GV-W89,90A, GV-W89,90P, or GV-W90A is strongly reduced.
(D) c-2-155 binding to immobilized GVD was monitored by
ELISA with anti-HSV antibodies in the presence or absence
of 1 or 5 mM of CaM or CAM1,2,3,4 and 0.5 mM Ca
2+. Results
are means ± SEM; n = 3.
See also Figure S2.
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V-ATPase and SNAREs in Neurotransmitter ReleaseVAMP2 TM is required to anchor VAMP2 in the yeast inner
nuclear membrane nearby its tetraspan binding partner. To
discriminate between these possibilities, we generated a
VAMP2 construct in which the TM was replaced by that of
the t-SNARE syntaxin1 (VAMP2-stxTM). VAMP2-stxTM inter-
acted with c-subunit, whereas FL syntaxin1 did not (Fig-
ure 1B). These results indicate that VAMP2 harbors a c-subunit
binding site located outside of its TM. VAMP2 TM is thus not
necessary for binding to c-subunit but confers transport of
VAMP2 to the inner nuclear membrane where the interaction
takes place.
V0 c-subunit is an extremely hydrophobic protein with four TM
domains connected by very short loops and discrete N and C
termini. Analysis of native proteins was unsuccessful because
both commercially available and specifically designed peptide
antibodies against exposed conserved regions of V0 c-subunit
failed to recognize rat proteins (data not shown). We therefore
expressed GFP-tagged full-length c-subunit (E-c-2-155) in
HEK293 cells. Pull-down assays detected the specific binding
of multimeric forms of E-c-2-155 to bacterially expressed GST-
VAMP2-2-92, the soluble cytoplasmic domain of VAMP (GVD),
but not to GST, immobilized on glutathione beads (Figures S1B
and S1C). These data indicate that c-subunit can associate270 Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc.with VAMP2 and that the TM region of VAMP is
not necessary for interaction, consistent with Y2H
data.
Because of limited expression yields in HEK293
and in order to address direct binding interactions,
we produced bacterially expressed tagged re-
combinant c-subunit. Major toxicity was encoun-
tered when overexpressing c-subunit in E. coli,
but was overcome by acidifying the culturemedium. A specific protocol to express and purify HSV-tagged
c-subunit was developed, which allowed the recovery of milli-
gram amounts of otherwise insoluble fusion proteins (Figure 2A,
left). The profile of c-2-155 expression in western blots showed,
in addition to monomers and dimers, higher-molecular-weight
c-subunit multimers that resisted dissociation by SDS. Pull-
down experiments via purified recombinant c-subunit and
immobilized GVD established a direct interaction (Figure 2A,
right). Mapping of c-subunit interaction sites on VAMP2 indi-
cated that only VAMP constructs containing the calmodulin
(CaM) binding motif at amino acids 77–92 (Quetglas et al.,
2000) bound to c-2-155 (Figure 2B). Furthermore, mutation of
juxtamembrane tryptophans (W89W90) known to be involved in
CaM binding (Quetglas et al., 2002) completely abolished
c-subunit binding (Figure 2C). To consolidate binding data, we
used soluble His-tagged VAMP2-DTM (HVD) to displace
c-subunit binding to immobilized GVD. As shown in Figure S2A,
a 10-fold molar excess of His-VAMP2DTM (HVD) reduced
c-subunit binding to background levels whereas HVDW89,90A
had no effect. ELISA assays with biotinylated, wild-type, or
mutated (W89,90A) VAMP2 peptides (amino acids 77–94) corrob-
orated delimitation of the binding domain on VAMP2, as well as
the importance of W89,W90 in c-subunit binding (not shown).
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Figure 3. c-Subunit Loop 3.4 Mediates Binding to VAMP2
(A) Binding of c-117-155 to VAMP2 immobilized on a sensor chip, monitored
by SPR (Biacore). c-117-155 or c-117-155-L3.4s (100 nM) were injected
(black bar) over captured His-VAMP2 (representative of four independent
experiments).
(B) Effect of L3.4, L3.4s, PH-L3.4, and PH-L3.4s on GVD binding to
immobilized full-length c2-155 in ELISA. In contrast to L3.4s and PH-L3.4s,
L3.4 as well as PH-L3.4 efficiently displaced binding. Results are mean ±
SEM; n = 3.
(C) Pull down of GVD and GV-W89,90P by immobilized PH-L3.4 or PH-L3.4s.
1 and 10 mM L3.4 displaced, respectively, 16% and 64% of GVD binding to
PH-L3.4.
See also Figure S3.
Neuron
V-ATPase and SNAREs in Neurotransmitter ReleaseWe also investigated the salt dependency of this interaction.
Pull-down experiments shown in Figure S2B revealed that
binding was promoted by increasing [NaCl] reaching amaximum
at 300 mM, but decreased thereafter. This corroborates the
importance of hydrophobic interactions, consistent with the
observation that tryptophans are important determinants in
c-subunit/VAMP2 binding.
In order to gain insight into the stoichiometry of c-subunit/
VAMP2 interaction, we performed pull-down experiments via a
fixed amount of GVD on glutathione beads and increasing
concentrations of c-subunit. Both flow through (FT) and bound
c-subunit, monitored by western blotting (Figure S2C), show
that below equimolar concentrations, almost no c-subunit was
detectable in FT. When concentrations superior to an equimolar
ratio of c-subunit/VAMP2 were attained, significant amounts of
c-subunit appeared in the FT and the c-subunit binding curved
displayed an inflection consistent with saturation. These data
suggest a binding stoichiometry of 1 c-subunit:1 VAMP2. Aggre-
gation or multimerization of c-subunit at high concentrations
probably underlies the nonsaturating component of binding.
Given that the CaM-binding domain of VAMP2 (aa 77–92), and
in particular W89,W90, are crucial for association with c-subunit,
we addressed the potential regulation of this interaction by
Ca2+/CaM. As shown in Figure 2D, ELISA assays via immobilized
GVD indicated a >85% decrease in c-subunit binding in the
presence of a large excess of CaM. Inhibition was dependent
on CaM activation by Ca2+ as shown by the fact that mutant
calmodulin (Keen et al., 1999) (CaM1,2,3,4), with impaired Ca
2+
coordination in both N- and C-lobes, did not compete with
c-subunit for binding to VAMP2. These results suggest that
mutually exclusive binding of CaM or c-subunit to VAMP2 might
be regulated by Ca2+ signaling.
To dissect the VAMP2 binding site on c-subunit, following up
on results obtained with Y2H, we used surface plasmon
resonance (SPR) analysis. The recombinant C-terminal region
of c-subunit, containing loop 3.4 (c-117-155) indicated high-
affinity binding to HVD (Figure 3A). This interaction was
completely abolished when loop 3.4 sequence was scrambled
in the c-117-155-L3.4s construct. Analysis of binding data
indicated a Kd = 1.9 ± 0.7 nM (Figure S3A). SPR data thus
substantiated Y2H assays, underlining the importance of
c-subunit loop 3.4 for binding to VAMP2.
In order to obtain a probe for functional experiments in
neurons, we synthesized a peptide corresponding to c-subunit
loop L3.4 (12 aa) and tested its capacity to interfere with
c-subunit binding to VAMP2. 10 mM L3.4 inhibited GVD binding
to immobilized full-length c-subunit by 36% in ELISA-based
assays (Figure 3B) and by at least 47% in pull-down assays
(not shown), reaching more than 60% in some experiments (Fig-
ure S3B). In contrast, L3.4s did not inhibit binding in ELISA and
inhibition reached only 10% in pull-down assays (Figure S3B).
We were also interested in determining whether the affinity of
this sequence for its target was affected by its native topology in
c-subunit, i.e., a short loop constrained by two flanking trans-
membrane anchors.We therefore inserted L3.4 peptide between
the antiparallel b strands 6 and 60 of the cytohesin plextrin
homology (PH) domain (Bedet et al., 2006). This construct has
been shown to scaffold an isolated protein sequence betweenNeuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc. 271
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Figure 4. V0 c-Subunit Loop 3.4 Peptide
Inhibits Neurotransmission at L5-L5
Excitatory Synapses
(A) Effect of the wild-type L3.4 peptide. Top, repre-
sentative examples of synaptic currents recorded
2 min (left) and 45 min (right in gray) after whole-
cell access. Bottom, time course of the inhibition
of the normalized synaptic current produced by
the peptide. Dotted line represents the baseline
level.
(B) Effect of the scrambled L3.4 s peptide. Note the
stability of synaptic transmission.
(C)Meanof normalizedEPSCsat 40min recording±
SEM (*p < 0.01, unpaired Student’s t test).
(D) Inhibition observed with bath application of
bafilomycin.
See also Figure S4.
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V-ATPase and SNAREs in Neurotransmitter Releasetwo rigid structures, mimicking a loop inserted between two
transmembrane domains (Bedet et al., 2006). ELISA experi-
ments with immobilized c-2-155 demonstrated that the con-
strained L3.4 sequence was approximately 10-fold more potent
than the linear peptide (Figure 3B) in displacing the interaction
with GVD. Pull-down assays (Figure 3C) on NiTA beads demon-
strated that immobilized PH-L3.4 specifically boundGVD but not
the W89,90P mutant. No binding was detected with PH-L3.4s.
10 mM of free synthetic L3.4 peptide inhibited this binding by
more than 60% (Figure 3C).
All these experiments were performed with VAMP2 constructs
devoid of its transmembrane domain and therefore do not
predict whether L3.4 can bind to VAMP2 anchored in a lipid
bilayer. Therefore, we reconstituted full-length VAMP2 in lipo-
somes and tested its accessibility to L3.4. ELISA experiments
showed that full-length wild-type VAMP2 proteoliposomes
specifically bound to immobilized L3.4, but not L3.4s. Further-
more, binding was abrogated by W89,90A mutation in VAMP2
(Figure S4A). In addition, SPR data indicated that neither L3.4
nor L3.4s peptides interact directly with phospholipids (Fig-
ure S4B). Altogether, these results indicate that synthetic L3.4
peptide, but not the scrambled sequence, effectively perturbs
the interaction between c-subunit and VAMP2 and can be
used to acutely probe its functional relevance by intraneuronal
injection.272 Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc.L3.4 Peptide Decreases Release
Probability in Connected L5-L5
Pyramidal Pairs
To address the physiological importance
of the interaction, we examined the ability
of L3,4 peptide to interfere with neuro-
transmitter release in acute rat cortical
slices. Dual recordings from connected
glutamatergic L5 pyramidal neurons (Fig-
ure 4A; Debanne et al., 2008) were
performed while injecting the synthetic
L3.4 peptide or its scrambled sequence
(L3.4s) into the presynaptic cell. Ten
minutes after whole-cell access to the
presynaptic neuron, EPSC amplitudeslowly but robustly decreased and stabilized to 54.8% ± 8.5%
(n = 7) of the control amplitude after 40 min (Figure 4B).
In contrast, no reduction in amplitude occurredwhen the presyn-
aptic pipette contained the scrambled L3.4 s peptide (103.7% ±
10.9%, n = 7; Figure 4C). Although reduced transmitter release is
likely to result from interference with the interaction between
VAMP2 and c-subunit, an alternative possibility must be
addressed. L3.4 peptide might interfere with intrinsic V-ATPase
subunit interactions and inhibit proton pump activity. This could
induce a default in vesicle loading with transmitter, leading to
‘‘firing blanks’’ (i.e., fusion of synaptic vesicles that are empty
or have reduced contents). We therefore compared the effects
on synaptic response amplitudes of a specific V-ATPase inhib-
itor bafilomycin A1, which induced a comparable reduction in
EPSC (48.4% ± 5.6%; n = 7; Figure 4D).
In order to rule out the possibility that the L3.4 peptide reduces
release by inhibiting the proton pump, we compared its effect on
release probability with that of bafilomycin A1. Although no
change was observed in paired pulse ratio (PPR) in neurons
injected with L3.4s peptide (97.7% ± 7.7%; n = 7; not shown),
a decrease in release probability, translated by an increase in
the paired pulse ratio (PPR), was observed in L3.4-injected
neurons (152.0% ± 15.3% of the control PPR, n = 7; Figure 5A).
Importantly, the opposite effect was observed in bafilomycin-
treated neurons in which, in accordance with a previous report
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Figure 5. Differential Effects of L3.4 and Bafilomycin on Paired-Pulse Ratio and Synaptic Vesicle Proton Pump Activity
(A) Changes in the paired-pulse ratio produced by L3.4. Top, representative examples of paired-pulse plasticity recorded 2 min (left) and 45 min (right in gray)
after whole-cell access. Bottom, time course of the normalized paired-pulse ratio. Note the increase in the paired-pulse ratio.
(B) Changes in the paired-pulse ratio produced by bafilomycin. Note the decrease in the paired-pulse ratio (red traces).
(C) Mean of normalized PPR after 40 min of recording (**p < 0.001, unpaired Student’s t test).
(D) Effects of L3.4 peptide or bafilomycin on synaptic vesicle acidification in vitro determined by monitoring acridine orange fluorescence. Arrows indicate
addition of Mg2+/ATP. In control and L3.4, the reaction was stopped (arrowheads) by adding EDTA.
See also Figure S5.
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V-ATPase and SNAREs in Neurotransmitter Release(Harrison and Jahr, 2003), a decrease in PPR (74.9% ± 5.7% of
the control, n = 7; Figure 5B) was measured. This clearly demon-
strates that the mechanisms underlying inhibition of neurotrans-
mitter release by L3.4 and bafilomycin are distinct, suggesting
that inhibition by L3.4 is likely to translate interference with the
VAMP2/c-subunit interaction rather than proton pump inhibition.
To directly address effects on proton pump activity, we per-
formed in vitro assays with synaptic vesicle-enriched membrane
fractions from rat brain. Intraluminal acidification by V-ATPase
was triggered by addition of Mg2+/ATP and monitored fluorimet-
rically by acridine orange quenching. Results demonstrated that
synaptic vesicle acidification was not affected at a concentration
as high as 1 mM L3.4 peptide (Figure 5D, left), although it was
robustly inhibited by bafilomycin (Figure 5D, right) or EDTA
(Figure S5). These data are consistent with the conclusion that
inhibition of neurotransmitter release by L3.4 peptide entails
decreased release probability and is not a consequence of
suppressing proton transport.L3.4 Peptide Inhibits Neurotransmitter Release
in Cholinergic Rat Superior Cervical Ganglion Neurons
In order to ascertain whether v-SNARE interactions with V0
might constitute a general presynaptic mechanism, we also
examined the action of L3.4 peptide at peripheral cholinergic
synapses. Superior cervical ganglion (SCG) neurons provide
a well-established culture system in which many agents that
perturb neurotransmitter release mechanisms have been
studied. Furthermore, unlike cortical neurons, SCG neurons
have extremely short axons, and therefore somatically injected
peptides reach nerve terminals very rapidly. Hence, this experi-
mental system allows direct evaluation of the kinetics of effects,
providing an indication as to which step in exocytosis is per-
turbed when a protein-protein interaction is disrupted (Ma and
Mochida, 2007).
When L3.4 was injected into SCG neurons, inhibition started
after around 1 min (1.1 ± 0.2 min, n = 6) (Figures 6A and 6B),
reaching a plateau within 10 min (11.6 ± 2.4 min, n = 6), whereasNeuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc. 273
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Figure 6. Effect of L3.4 on Cholinergic Neurotransmission
(A1) Excitatory postsynaptic potentials (EPSPs) from one representative experiment recorded 1 min before (black) and 5 (blue) and 20 (cyan) min after the start of
3 min presynaptic injection of L3.4 (1.5 mM in the injection pipette). (A2) The first order derivative of EPSPs before (black) and 20 min after (cyan) L3.4 injection
shown in (A1). Pink dotted line indicates the peak of EPSPs. (A3) The peak amplitude of EPSPs shown in (A1) was normalized to that before the injection.
(B) Smoothed values of normalized and averaged EPSP (n = 6–7). EPSP was recorded every 10 s in the presence of L3.4, L3.4s, VAMP77-94, or VAMP77-94m
(1.5 mM of each peptide in the injection pipette).
(C) Decrease in amplitudes of EPSP elicited by 0.1, 0.25, and 0.5 Hz (n = 5–8) action potentials at 20min after peptide injection. Mean ± SEM. **p < 0.01; *p < 0.05,
unpaired Student’s t test.
(D) Normalized EPSP amplitudes (mean ± SEM) during and after depletion of synaptic vesicles by 900 action potentials at 5 Hz. The line shows smoothed values.
At 15 min after starting injection of 1.5 mM L3.4 (n = 7), EPSP amplitudes were measured every 1 s. After 1 min of EPSP recording, the train of stimuli (gray
horizontal bar) was applied.
(E) As in (D) but with L3.4s (n = 7).
(F) Recovery of EPSP amplitude at 1 min and 5 min after the end of the train of stimulation in the presence of L3.4 (yellow) or L3.4s (green). At 1 min, p = 0.80
(L3.4 versus L3.4s). At 5 min, p = 0.67 (L3.4 versus L3.4s). Unpaired Student’s t test.
See also Figure S6.
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V-ATPase and SNAREs in Neurotransmitter Releasethe scrambled peptide L3.4 s had no effect (Figure 6B). This rapid
inhibition is comparable to that observed with agents that affect
a late step in exocytosis (Mochida, 1998). To corroborate these
results, we injected a VAMP2 peptide (VAMP77-94) correspond-
ing to the c-subunit binding site (aa 77–92) and a control peptide
with the W89,90A mutation (VAMP77-94m) that abrogates
binding to c-subunit. Wild-type VAMP2 peptide induced a very
similar level of inhibition and onset to L3.4. VAMP77-94m like
L3.4s had no effect on neurotransmission (Figures 6B and 6C).
The time to peak of the decreased EPSP wave form was not
affected by L3.4 (Figure 6A1); however, the speed of rise to the
peak (Figure 6A2) and the decay from the peak were slightly
slower (Figure 6A3), suggesting that the kinetics of synaptic274 Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc.vesicle fusion might be modified in the presence of the peptide.
In agreement with experiments in cortical pairs, an effect of the
peptide on proton pumping and thus on acetylcholine transport
during vesicle recycling appears unlikely because the EPSP
decrease was independent of stimulation frequency (synaptic
activity) (Figure 6C; Ma and Mochida, 2007; Su et al., 2001).
Furthermore, in these strong peripheral synapses, inhibition by
microinjected bafilomycin A1 displayed onset at around 40 min
at 0.2 Hz (Figure S6), which was very slow compared to that of
L3.4 peptide at an even lower stimulation frequency (Figure 6B).
In order to confirm that L3.4 did not interfere with the classical
recycling pathway, reserve vesicles and the rapidly releasable
vesicle pool were depleted by a 3 min train of presynaptic action
Neuron
V-ATPase and SNAREs in Neurotransmitter Releasepotentials at 5 Hz (Lu et al., 2009;Ma andMochida, 2007) and the
recovery of EPSP amplitude was measured every 1 s. At the end
of the train, the EPSP amplitude was within baseline noise levels
(Figures 6D–6F), and subsequently recovered at two distinct fast
and slow rates. L3.4 did not affect the recovery rates from syn-
aptic vesicle depletion by either a 5 Hz train (Figures 6D–6F) or
a 10 Hz train (data not shown). Together, these results consoli-
date data from L5-L5 synapses. Furthermore, they indicate
that L3.4 peptide does not affect vesicle recycling and thus are
consistent with the view that it perturbs the interaction of
VAMP2 and c-subunit of V-ATPase V0 at a late step of exocy-
tosis, close to fusion.
DISCUSSION
Analysis of links between SNAREs and V-ATPase subunits by
Y2H, GST pull-down from lysates of transfected HEK293 cells,
and direct binding studies with bacterially expressed proteins
has uncovered a direct molecular interaction between the
v-SNARE VAMP2 (synaptobrevin) and V0 c-subunit. The
c-subunit binding domain on VAMP2 was mapped to the juxta-
membrane region, which also constitutes a calmodulin-binding
motif (Quetglas et al., 2000). We delimited the VAMP2 binding
site on c-subunit to the loop 3.4. Thus, the association occurs
via two cytoplasmically oriented and membrane-proximal
sequences, which is topologically consistent with a cis interac-
tion between intrinsic vesicle membrane proteins. Dynamic
regulation of this interaction is suggested by its displacement
by Ca2+/CaM and by its dependence on the lipid environment.
In fact, the presence of phosphatidylserine in VAMP2 liposomes
inhibited L3.4 peptide binding (not shown). This is consistent
with previous studies indicating that phosphatidylserine seques-
ters VAMP2 precluding SNARE assembly. The amphiphilic lipid
sphingosine can displace phosphatidylserine and reactivate
VAMP2 for exocytosis (Darios et al., 2009). It will be interesting
to determine whether sphingosine also regulates interactions
between VAMP2 and c-subunit.
In order to assess the functional relevance of this interaction,
we chose acute peptide interference in synaptically coupled
pairs of neurons. We measured neurotransmitter release by
monitoring postsynaptic responses after presynaptic injection
of the loop 3.4 peptide (L3.4) sequence in two different neuronal
systems. This approach allowed us to analyze the kinetics of the
onset of inhibition in a given pair and to determine whether
effects occur during vesicle recycling or at later steps, close to
fusion. Glutamatergic neurotransmission between two con-
nected pairs of pyramidal neurones in acute cortical slices was
robustly inhibited by loop 3.4 peptide injection whereas the
scrambled peptide had no effect. Inhibition was not exclusive
to glutamatergic synapses since cholinergic neurotransmission
in SCG neuronal cultures was also inhibited, though to a lesser
extent (22%) than in cortical neurons. Practically identical effects
were observed upon injection of a VAMP2 peptide, correspond-
ing to the juxtamembrane domain that binds L3.4. This result is
consistent with the idea that both peptides act by disrupting
the interaction between c-subunit and VAMP2. The difference
in the extent of inhibition between cortical and SCG neurons
may be due to the different mode of peptide injection. Peptidewas transiently microinjected (3 min) into SCG neurons, whereas
it diffused constantly into cortical neurons from a recording
patch electrode.
Because L3.4 peptide mimics a c-subunit cytoplasmic linker
sequence, we were concerned that it might modify intramolecu-
lar interactions between V-ATPase subunits and inhibit proton
pumping, which would then compromise neurotransmitter
loading into synaptic vesicles. In this case empty vesicles might
still fuse without generating an EPSP, and therefore a reduced
EPSP could result from blockade of the proton pump. Several
observations allow us to rule out this possibility. First we
compared the effects on neurotransmission of L3.4 peptide
with those of bafilomycin A1, a specific inhibitor of the V-ATPase
that blocks proton transport. In the strong synapses of peripheral
SCG neurons, bafilomycin A1 modified EPSPs only after pro-
longed stimulation, whereas L3.4 peptide reduced EPSPs
much more rapidly, even with lower stimulation frequencies.
This observation is consistent with the idea that bafilomycin
affects a step in vesicle recycling (e.g., reduced loading with
transmitter resulting from a defective proton gradient) whereas
L3.4 peptide inhibits a downstream step closer to vesicle fusion.
As expected in the weaker synapses of central glutamatergic
neurons, the onset of inhibition by bafilomycin was faster and
induced gradual inhibition of EPSCs similar to that observed
with L3.4. However, the effects of bafilomycin and L3.4 on
short-term plasticity were completely different. L3.4 increased
the paired pulse ratio (PPR) by more than 52% whereas bafilo-
mycin produced the opposite effect with a PPR decrease of
about 25%. Finally, high concentrations of L3.4 peptide had no
effect on bafilomycin-sensitive proton transport by V-ATPase
in vitro, in a membrane fraction enriched in synaptic vesicles.
All these results indicate that the inhibition of neurotransmitter
release by L3.4 peptide is not a consequence of perturbing
V-ATPase proton pump activity. In addition, we demonstrated
that L3.4 peptide had no affinity for lipids and thus is unlikely
to perturb exocytosis by destabilizing membrane organization.
In SCG neurons, microinjected peptides reach nerve terminals
very rapidly. The L3.4 as well as VAMP77-94 peptides induced
prompt inhibition (onset at around 1 min), which is typical of
agents that perturb neurotransmission at late steps in exocytosis
(e.g., SNARE-interacting Synprint peptide from voltage-gated
N-type calcium channel) (Mochida et al., 1996), P/Q type calcium
channel blockers (Mochida et al., 2003). Consistent with this
interpretation, the L3.4 peptide induced a slightly slower speed
of rise and decay of the EPSP, suggesting that the kinetics of
synaptic vesicle fusion might be modified in the presence of
the peptide. Furthermore, experiments involving high-frequency
stimulation and recovery, to examine whether L3.4 peptide
perturbed the classical recycling pathway, indicated that it did
not modify the refilling rate of the readily releasable or reserve
vesicle pools. Hence, taken together, these results suggest
that inhibition by L3.4 takes place at a step close to Ca2+
triggering and fusion pore opening. Further investigation is,
however, needed in order to precisely identify the molecular
step at which L3.4 acts.
Therefore, our present data, obtained with the c-subunit
domain that binds v-SNAREs as a probe, supports the hypoth-
esis that V0 sector is involved in vesicle fusion. PublishedNeuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc. 275
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imal partner sequence in VAMP2. VAMP2 W89W90 residues
are involved in binding Ca2+/CaM and acidic phospholipids
(Quetglas et al., 2002) and contribute to SNARE complex dimer-
ization (Fdez et al., 2008). Interestingly, we now report that
Ca2+/CaM inhibits c-subunit binding to VAMP2. Mutagenesis
has underscored a role for juxta-membrane tryptophans in
Ca2+-dependent exocytosis from PC12 cells (Quetglas et al.,
2002) and neurons (Maximov et al., 2009). Expression of the
VAMP2 W89,90A mutant in VAMP2 KO neurons induced a 2-fold
decrease in evoked release compared to wild-type rescue but
did not affect SNARE assembly nor binding of complexin or
synaptotagmin to the SNARE complex (Maximov et al., 2009).
What might be the rationale for V0 c-subunit cooperation with
SNARE proteins in neurotransmitter release? As yet we can only
speculate. First, c-subunits might become available for VAMP2
binding only upon dissociation of the V1 sector, when optimal
proton content and neurotransmitter transport into the vesicle
have been achieved (Morel et al., 2003). This could provide a
regulatory link between vesicle filling and the later steps in
exocytosis. Our previous work suggested that Ca2+/CaM com-
petes with acidic phospholipids for binding to the membrane-
proximal region of VAMP2 and can switch interactions with lipids
from cis to trans leaflets (de Haro et al., 2004). An extension to
this hypothesis would be that a fraction of the VAMP2molecules
display cis interactions with c-subunits, rather than lipids, and
these interactions arrest SNARE zippering. In this model,
c-subunits might act in concert with the complexin accessory
helix that mimes VAMP2 C-terminal domain and binds to
t-SNAREs (Giraudo et al., 2009). Displacement of c-subunit by
Ca2+/calmodulin could thus reactivate VAMP2 for completion
of zippering. However, displacement appears to be inconsistent
with the idea that VAMP2 is a scaffold positioning c-subunits for
a role in membrane fusion. Could the V0 domain contribute to
forming the fusion pore? Intriguingly, c-subunits purified from
Torpedo (reviewed by Morel et al., 2001) or yeast (Peters et al.,
2001) have been reported to form a regulated pore in vitro.
Evidence from yeast led to the suggestion that SNARE pairing
precedes the assembly of trans V0-V0 complexes that delineate
a channel-like structure at the fusion site (Peters et al., 2001).
However, yeast vacuolar fusion still occurs, although severely
impaired, when V0 is present in only one of the two partner
membranes destined to fuse (Bayer et al., 2003). Further investi-
gations in neurons, for example via point mutations that specifi-
cally affect a precise binary interaction, will be necessary to
understand the precise role of c-subunit interaction with
VAMP2 in neurotransmitter release and the mechanisms of its
regulation by Ca2+/CaM.EXPERIMENTAL PROCEDURES
Reagents
All oligonucleotides were purchased from MWG Biotech (Germany). Yeast
two-hybrid vectors and strains were purchased from OriGene Technologies,
Inc. (Rockville, MD). Glutathione sepharose was from GE Healthcare and
Ni-NTA agarose from QIAGEN. Lipids were from Avanti Polar Lipids. Peptides
(L3.4: GVRGTAQQPRLF; L3.4s: GQATVQPLGRRF) were synthesized by
Activotec (Southampton, UK) and (VAMP77-94: FETSAAKLKRKYWWKNLK;
VAMP77-94m: FETSAAKLKRKYAAKNLK) by GenCust Europe (Luxembourg).276 Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc.All protein purifications were performed in the presence of protease inhibitors
(Complete, Roche).
Expression Constructs and Cloning Procedures
All sequences are from rat. For Y2H studies, VAMP2 constructs were either full
length or contained syntaxin transmembrane domain VAMP2-STXTM. Except
for two-hybrid studies where full-length VAMP2B was used, all VAMP2B
constructs lacked a transmembrane domain (TM) (amino acids 2–92). All
constructs were generated by standard polymerase chain reaction (PCR) via
a commercial Y2H adult rat brain cDNA library (Origine). VAMP2 construct
encompassing residues 2–92 (forward 50-GCGAATTCTCGGCTACCGCTGC
CAC-30 + reverse 50-GCGTCGACTTAGTTTTTCCACCAGTATTTGCG-30)
was amplified and inserted between EcoR1 and Sal1 sites of pGEX4T-1
(GVD). VAMP2 2-31 (forward 50-GCGAATTCTCGGCTACCGCTGCCAC-30 +
reverse 50-GCGTCGACTTACAGTCTCCTGTTACTGGTAAG-30), VAMP2 28-76
(forward 50-CGAATTCAGTAACAGGAGACTGCAGC-30 + reverse 50-GCGTC
GACTTACTGGGAGGCCCCTGCCTG-30), and VAMP2 28-92 (forward 50-CGA
ATTCAGTAACAGGAGACTGCAGC-30 + reverse 50-GCGTCGACTTAGTTTT
TCCACCAGTATTTGCG-30) were amplified and inserted between EcoRI and
SalI restriction sites into pGEX-5X-1 (respectively, GV-2-31, GV-28-76, and
GV-28-92). His-tagged VAMP2-2-92 (HVD) was also obtained by inserting
VAMP2 in pET28a with EcoRI and SalI sites. Site-directed mutagenesis
(Stratagene) was used to introduce point mutations and generate His-tagged
VAMP2-2-92-W89,90A (HV-W89,90A) and GST-tagged VAMP2-2-92-W89,90A
(GV-W89,90A; forward 5
0-GCGAATTCTCGGCTACCGCTGCCAC-30+ reverse
50-GCGTCGACTTAGTTTTTcgccgcGTATTTGCG-30), GST-VAMP2-2-92-W90A
(GV-W90A; forward 5
0-CTCAAGCGCAAATACTGGccgAAAAACTAAGTCG
AG-30 + reverse 50-CTCGACTTAGTTTTTcggCCAGTATTTGCGCTTGAG-30),
as well as GST-VAMP2-2-92-W89,90P (GV-W89,90P; forward 5
0-CTCAAGCG
CAAATACccgccgAAAAACTAAGTCGAG-30 + reverse 50-CTCGACTTAGTT
TTTcggcggGTATTTGCGCTTGAG-30). The following primers were used for
VAMP2-STXTM (forward 50-GCGAATTCTCGGCTACCGCTGCCAC-30 +
reverse 50-GCGTCGACCTATCCAAAGATGCCCCCGATGGTGGAGGCGATG
ATGATGCCCAGAATCACACAGCAAATGATGATCATGATGTTTTTCCACCAG
TATTTGCG-30). The reverse primer covers the TM of syntaxin and residues 86
to 92 of VAMP2. VAMP2-2-92 was used as a matrix for this PCR. HSV tag
(QPELAPEDPED) was introduced as follows at the 50 of pET28a (Novagen)
‘‘multiple cloning site’’ to generate pET28-HSV-Nter: 50 phosphorylated
primers encoding HSV tag sequence (forward 50-GATCCCAGCCTGAAC
TCGCTCCAGAGGATCCGGAAGATG-30 reverse 50-AATTCATCTTCCGGAT
CCTCTGGAGCGAGTTCAGGCTGG-30) were annealed and ligated to
BamH1, EcoR1 open pET28a. Full-length V0 c-subunit (residues 2–155) was
amplified and inserted between Sac1 and Sal1 of pEGFPc3 and pET28a-
HSV-Nter to generate pEGFPc3-c-2-155 and pET28-HSV-c-2-155, respec-
tively. All truncated c-subunit constructs were amplified by PCR and cloned
between EcoR1 and Sal1 sites in pEGFPc2, pET28a-HSV-Nter, or EcoR1
and Xho1 for the yeast two-hybrid vectors (Origine): pGilda (for c-subunit)
and pJG-4-5 (for VAMP2). The following c-subunit truncation constructs
were thus prepared: pEGFPc-2-c2-155 (E-c-2-155); pGilda-c2-155 (BD-c2-
155); pGilda-c-2-76 (BD-c-2-76); pGilda-c-2-36 (BD-c-2-36); pGilda-c-37-
155 (BD-c37-155); pGilda-c-77-155 (BD-c-77-155); pGilda-c-117-155 (BD-
c-117-155). BD-c-2-155 (full-length), BD-c-2-76 (from the N terminus until
the end of TM2), BD-c-2-36 (from the N terminus until the end of TM1),
c-37-155 (from the beginning of loop 1.2 until the C terminus), c77-155 (from
the beginning of loop 2.3 until the C terminus), c-117-155 (from the beginning
of loop 3.4 until the C terminus). c-117-155 with scrambled loop 3.4 sequence
(GQATVQPLGRRF/ggtcaggccactgtccagcctctgggccggcgattc) pET28a-HSV-
c-117-155-L3.4s (c-117-155-L3.4 s) was generated by PCR suing the fol-
lowing primers (forward 50- gcgaattcggtcaggccactgtccagcctctgggccgg-30 +
reverse 50- gcgtcgacCTACTTTGTGGAGAGGATTAG-30 ) on a matrix of a
full-length c-subunit construct with scrambled loop 3.4 sequence pET28a-
HSV-c-2-155-L3.4s (c-2-155-L3.4s). This later construct was made as follows
with three consecutive PCRs: with Platinum TaqDNApolymerase (Pfx) (Invitro-
gen) and as amplification matrix pET28a-HSV-c-1-155, overlapping PCR
fragments were generated with (a) 1- EcoR1 flanked c-subunit forward primer
(50-GCGAATTCGCTGACATCAAGAACAACCC) and 2- reverse encoding the
scrambled L3.4 sequence (50- gaatcgccggcccagaggctggacagtggcctgaccAG
Neuron
V-ATPase and SNAREs in Neurotransmitter ReleaseCATCTCCGACAATGCC-30 ) (b) 3- forward primer encoding the scrambled
L3.4 sequence (50-ggtcaggccactgtccagcctctgggccggcgattcGTGGGCATGA
TCCTGATCC-30) and 4- a Sal1 flanked reverse T7 terminator primer (50-G
CTAGTTATTGCTCAGCGG) that primes 30 to the vector multiple cloning site.
One tenth of both purified newly generated fragments were mixed in the pres-
ence of Pfx and in the absence of additional primers or matrix and subjected to
10 cycles to generate the new mutated matrix. Primers 1 +4 were then added
to the tube and cycling continued to amplify the full-length mutated construct.
The consequent PCR product was digested with EcoR1 + Sal1 and ligated to
pET28a-HSV-Nter.
PH-L3.4 and PH-L3.4s were constructed as follows: with BbsI and SalI
restriction sites, L3.4 and scrambled L3.4 s encoding phosphorylated comple-
mentary oligonucleotides were introduced between b strands 6 and 60 of the
PH domain of human cytohesin1 in pET21d (Bedet et al., 2006). PH-L3.4:
forward primer (50-aggccGGTGTCCGGGGCACTGCCCAGCAGCCTCGAC
TGTTCg-30); reverse primer (50- tcgacGAACAGTCGAGGCTGCTGGGCAG
TGCCCCGGACACCg-30). PH-L3.4 s: forward primer (50- aggccGGTCAGGCC
ACTGTCCAGCCTCTGGGCCGACGGTTCg-30); reverse primer (50- tcgacGA
ACCGTCGGCCCAGAGGCTGGACAGTGGCCTGACCg-30). Wild-type and
mutant calmodulin in pGEX-4T1 (GST-CaM and GST-CaM1,2,3,4) were gifts
from Amy Lee (Emory University, Atlanta). GST-CaM1,2,3,4 with four impaired
Ca2+ coordination sites was modified by PCR to introduce a Factor Xa
cleavage site upstream of the CaM sequence. Full-length VAMP2 construct
(VAMP2-myc-his) was a gift from G. Schiavo (London Research Institute,
London).
Yeast Two-Hybrid Analysis
c-2-155 constructs were made in pGilda bait vector and VAMP2 in the prey
vector pJG4-5. Lithium acetate was used to transform yeast cells (EGY48
strain) according to classical procedures. Binary interactions were probed
by transforming bait and prey vectors into yeast cells containing the b-galac-
tosidase encoding plasmid (pSH 18-34). To probe for protein interactions,
transformants were plated on selection plates (-Ura, -Trp, -Leu, -His) contain-
ing X-gal.
Bacterial Protein Expression
VAMP2 and c-subunit were expressed in Rosetta2 bacteria (Novagen).
VAMP2 constructs were expressed via classical protocols. Crude superna-
tants of ultracentrifuged ‘‘French press’’ bacterial lysates were stored at
20C. Bacterial strains expressing c-subunit constructs were cultured in
pH 5.7 phosphate-buffered LB medium and protein expression was induced
with 1 mM IPTG for 4–5 hr. Bacterial pellets were stored at20C until protein
purification. GST-CaM and GST-CaM1,2,3,4 were expressed in BL21.
Purification of His-HSV-Tagged c-Subunit Constructs
Ten grams of dry bacterial pellet were resuspended in 100 ml of buffer A
(10 mM Tris-Cl, 100 mM NaH2PO4 [pH 8.0], 500 mM NaCl, 6 M GuCl, 1%
CHAPS [w/v], 20% glycerol, 20 mM imidazole, 10 mM b-mercaptoethanol).
The extract was sonicated to achieve complete homogenization and incu-
bated overnight in the presence of DNase I (20 mg/ml) at 4C with 2–3 ml of
Ni-NTA beads (QIAGEN), prewashed with buffer A. Beads were then loaded
in a column and subjected at gravity flow to successive washes with buffer
A containing decreasing amounts of GuCl (4 M, 2 M, 0.5 M, 0 M). A last
wash with buffer B (20 mM HEPES [pH 7.5], 150 mM NaCl, 0.5% CHAPS)
was performed before collecting purified and renatured proteins by elution
at 4C in buffer B containing 250 mM imidazole. Protein concentration was
determined with the micro BCA assay (Pierce) and eluted proteins were stored
at 20C in single-use aliquots.
Purification of GST and His-Tagged SNAREs
Bacterial pellets containing His-tagged proteins were French pressed in
20 mM Tris (pH 8.0), 500 mM NaCl, 10% glycerol buffer and purified on
Ni-NTA beads. A last wash was made by adding to the French press buffer
50 mM imidazole and 0.5 mMDTT. Proteins were eluted in French press buffer
containing 500 mM imidazole and 0.5 mM DTT and dialyzed overnight against
25 mM HEPES (pH 7.4), 140 mM KCl, and 0.5 mM DTT. Protein aliquots were
stored at 80C. Bacterial pellets of GST-tagged VAMP2-2-92 (GVD) andVAMP2-2-92-W89,90A (GV-W89,90A) were French pressed in 25 mM Tris
(pH 8.0), 150 mM NaCl buffer and purified on glutathione Sepharose beads
in the presence of 0.1% Triton X-100. Proteins were eluted in Tris 50 mM
(pH 8.0), 10 mM reduced glutathione and frozen at 20C until used. For
full-length VAMP2 preparations, buffers were supplemented with 0.4%
CHAPS.
Purification of Wild-Type and Mutant Calmodulin
Bacterial pellets containing GST-tagged proteins were French pressed in
25 mM Tris (pH 7.5), 150 mM NaCl. Fusion proteins were purified on gluta-
thione-sepharose beads in the presence of Triton X-100. After washing with
25 mM Tris (pH 7.5), 150 mM NaCl, and 10 mM CaCl2, wild-type CaM and
mutant CaM1,2,3,4 were eluted by Thrombin and Factor Xa cleavage, respec-
tively, according to the manufacturer’s instructions. Proteins were dialyzed
against HEPES 25 mM (pH 7.4), KCl 140 mM and stored at 20C in 10%
glycerol.
Pull-Down Experiments
With standard procedures, VAMP2 constructs were freshly purified on
glutathione beads from frozen cleared bacterial extracts. Per tube, a 1 ml
mixture of 1 mM GST and GST-VAMP2 constructs (GVD, GV-2-31, GV-28-
76, GV-28-92, GV-W89,90A, GV-W89,90P, or GV-W90A) was immobilized. For
E-c-2-155, pretransfected HEK293 cells from a 10 cm culture dish were
solubilized in 1 ml of 25 mM Tris (pH 7.5), 150 mM NaCl, 1% CHAPS supple-
mented with protease inhibitors (Complete, Roche). One-fifth of this extract
was incubated with the corresponding preloaded glutathione bead pellet.
For HSV-tagged c-2-155, 2–10 nM was added to the corresponding gluta-
thione beads in 1 ml binding buffer: 25 mM Tris (pH 7.5), 150 mM NaCl,
0.5% CHAPS. For the salt sensitivity assay, 30 nM HSV-tagged c-2-155 was
used in 25 mM Tris (pH 7.5), 0.5% CHAPS supplemented with the indicated
concentrations of NaCl. Saturation studies were made with 1 mM GVD and
indicated concentrations of HSV-tagged c-subunit. His-tagged HSV-c-2-
155, PH-L3.4, or PH-L3.4s were freshly purified on Ni2+ beads. Per tube,
100 nM purified GVD or GV-W89,90A was added in the presence of L3.4 or
L3.4s (1 and 10 mM).
In all conditions, incubation was overnight at 4C. Beads were washed four
times with binding buffer and bound proteins were eluted in SDS sample
buffer. For saturation studies, supernatants were collected and TCA precipi-
tated. Proteins were separated by SDS-PAGE and c-subunit binding to
VAMP2 was probed by western blotting with either monoclonal anti-GFP
(Roche) or polyclonal anti-HSV antibodies (AbCaM) (1:2500) and Immobilon
western (Millipore) or super signal West pico (Pierce) HRP chemiluminescence
substrates. GVD binding to immobilized c-2-155 or PH constructs was probed
with goat polyclonal anti-GST antibodies (GE healthcare). Quantifications were
carried out with ImageJ.
ELISA
Nunc Maxisorp 96-well plates were coated overnight with L3.4 or L3.4s
(10 mg/ml), purified GST, GVD, or His-HSV-c-2-155 (2 mg/ml) in 100 mM
NaHCO3 (pH 8.9) buffer. For His-HSV-c-2-155, after a 1 hr blocking step
with 25 mM Tris (pH 7.5), 150 mM NaCl, 1% casein, 0.05% Tween 20,
300 nM GVD, or GV-W89,90P in 25 mM Tris (pH 7.5), 150 mM NaCl, 0.1%
BSA, 0.05% Tween 20 was added in the presence or absence of increasing
concentrations of L3.4 or L3.4 s peptides. GST and GVD-coated plates were
blocked for 1 hr with 25 mM Tris (pH 7.5), 150 mM NaCl, 1% BSA, 0.05%
Tween 20, 0.5% CHAPS. With the same buffer containing 0.5 mM CaCl2,
the wells were incubated overnight with 30 nM HSV-c2-155 and purified
recombinant CaM or CaM1,2,3,4. Wells coated with L3.4 and L3.4s were
blocked for 2 hr at 37C with 25 mM Tris (pH 7.5), 150 mM NaCl, 1% casein.
1 mM VAMP2-myc-his or VAMP2-W89,90A-myc-his liposomes were added to
the wells in blocking buffer and incubated for 2 hr at 37C. GVD, HSV-tagged
c-2-155, and VAMP2-myc-his binding were probedwith anti-GST (1:7500) (GE
Healthcare), anti-HSV (AbCaM) (1:2500), or a monoclonal custom-made
anti-VAMP2 antibody (GeneCust Europe, Luxembourg), respectively. The
chromogenic HRP substrate TMB (3,30,5,50-tetramethylbenzidine) was then
used to detect the binding of HRP-coupled secondary antibodies (Jackson
ImmunoResearch).Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc. 277
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The following protocol was inspired from Goncalves et al. (2000) with modifi-
cations: four rat brains were homogenized in 0.32 M sucrose, 10 mM
HEPES-KOH, 0.2 mM EGTA in the presence of protease inhibitor cocktail
(Sigma), then centrifuged for 10 min at 900 3 g. 3 ml of supernatant were
layered onto a 4 ml 0.8 M sucrose cushion and centrifuged 20 min at
257,0003 g. Synaptosome pellets were then resuspended in hypotonic buffer
(10 mM Tris-HCl [pH 8.5], 1 mM PMSF) and centrifuged 20 min at 40,0003 g.
The synaptic vesicle-enriched supernatant was then adjusted to 10 mM Tris-
HCl (pH 8.5), 60 mM sucrose, 140 mM KCl, 2 mM MgCl2, 50 mM EGTA (assay
buffer). ATP-dependent proton transport was monitored by the quenching of
acridine orange (AO) fluorescence. When the synaptic vesicle lumen is acidi-
fied, membrane-permeable AO becomes protonated and trapped within the
synaptic vesicle. The high AO concentration achieved results in a red-shift
and self-quenching of fluorescence. In 100 ml final reaction buffer, a 5-fold
dilution of enriched synaptic vesicle preparation was incubated at 30C in
the presence of 2 mM AO (Sigma). Proton uptake was triggered by adding
500 mMMg-ATP. Experiments were carried out in Nunclon fluorescence plates
with a Biotek Sirius HT injector plate reader and KC4 software. Fluorescence at
525 nm was monitored with data acquisition every 15 s.
Preparation of Liposomes and Proteoliposomes
850 nmoles of dried lipids were used in each case. To prepare protein-free
liposomes, 85% mol/mol 1-palmitoyl, 2-oleoyl phosphatidylcholine + 15%
1,2-dioleoylphosphatidylserine were resuspended in 25 mM HEPES-KOH
(pH 7.4), 140 mM KCl, 0.25 mM DTT, 1.5% (w/v) sodium cholate (Sigma).
When preparing VAMP2-myc-his proteoliposomes, 1-palmitoyl, 2-oleoylphos-
phatidylcholine was resuspended as above in the presence of VAMP2 at a
1/100 (mol/mol) protein-to-lipid ratio. Liposomes and proteoliposomes were
obtained by rapid dilution and extensive dialysis in the resuspension buffer
without detergent.
Binding Analysis by SPR
SPR experiments were conducted at 25C with a Biacore 3000 (GE Health-
care). Purified HVD (2000–3000 resonance units [RU]) was covalently coupled
in 10 mM sodium acetate (pH 5) to a CM5 chip via amine group linkage
with standard coupling procedures (Quetglas et al., 2002). c-117-155 or
c-117-155-L3.4s were injected at 30 ml/min with Kinject mode in HBS EP
(10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, 0.005% surfactant
P20) containing Triton X-100 0.005% as running buffer. All flow cells were
regenerated for 40 s between samples with 50 mM octylglucoside diluted in
running buffer. Data obtained over a nonfunctionalized flow cell were sub-
tracted from all runs to account for nonspecific binding (less than 5% of total
binding). Interactions were fitted globally across all concentrations to a 1:1
Langmuir binding model and rate constants were derived with BIA Evaluation
4.1 software. The affinity constant, KD, was calculated from the ratio of the rate
constants kd (dissociation rate) versus ka (association rate). To measure
peptide interactions with lipids, protein-free liposomes (PC or PS/PC) were
immobilized on an L1 sensor chip to generate a stable lipid surface. PC lipo-
somes were immobilized in the control flow cell and experiments were con-
ducted as described (de Haro et al., 2004) with 16 mMNaOH for regeneration.
Preparation, Recording, and Data Analysis from Cortical Slices
Cortical slices and dual whole-cell recordings were obtained as detailed
previously (Boudkkazi et al., 2007). Loop 3.4 (L3.4) or scrambled (L3.4s)
synthetic c-subunit peptides were injected (2 mM) into the presynaptic
neurons. Bafilomycin A1 was purchased from Euromedex (France) and was
bath applied (final concentration, 5 mM). All paired-pulse protocols were per-
formed at a frequency of 20 Hz. Synaptic responses were averaged according
to alignment of the presynaptic action potentials with automatic peak detec-
tion (Detectivent 4.0, N. Ankri INSERM). Data are means ± SEM.
Synaptic Transmission from SCG Neurons
6- to 8-week cultures, EPSP recording, and injection of peptides (1.5 mM;
5 mM showed no further effect) were performed as described previously
(Mochida et al., 1994). EPSPs were recorded at 0.1, 0.25, or 0.5 Hz. The
peak amplitudes were normalized to the values before injection. The averaged278 Neuron 67, 268–279, July 29, 2010 ª2010 Elsevier Inc.and smoothed values (Origin 7.5) obtained from an eight-point moving average
algorithm were plotted against recording time with t = 0 corresponding to the
start of 3 min presynaptic injection of L3.4, L3.4s (a scrambled control
peptide). Data are mean ± SEM. A two-tailed Student’s t test was applied as
indicated.
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